Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia

Lipids in Health and Disease

Volumn 8, Issue , 2009, Pages

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^b   Kosugi, Rie ^b   Hatakeyama, Yuko ^b   Yoshida, Yuki ^b   MacHida, Yoji ^b   Aoyama, Naoyoshi ^b   Masuda, Takashi ^a   Izumi, Tohru ^b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AZETIDINE DERIVATIVE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77956854496     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-8-41     Document Type: Article

References (45)

1. Atherosclerosis - an inflammatory disease. R Ross, The New England journal of medicine 1999 340 2 115 126 10.1056/NEJM199901143400207 9887164 (Pubitemid 29054847)
2. The immune response in atherosclerosis: a double-edged sword. GK Hansson, P Libby, Nature reviews 2006 6 7 508 519 16778830 (Pubitemid 43980523)
3. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. C Weber, A Zernecke, P Libby, Nature reviews 2008 8 10 802 815 18825131
4. Immune and inflammatory mechanisms of atherosclerosis (*). E Galkina, K Ley, Annual review of immunology 2009 27 165 197 10.1146/annurev. immunol.021908.132620 19302038
5. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. HE Andrews, KR Bruckdorfer, RC Dunn, M Jacobs, Nature 1987 327 6119 237 239 10.1038/327237a0 3106833 (Pubitemid 17071052)
6. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. H Cai, DG Harrison, Circulation research 2000 87 10 840 844 11073878
7. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. HE Bays, PB Moore, MA Drehobl, S Rosenblatt, PD Toth, CA Dujovne, RH Knopp, LJ Lipka, AP Lebeaut, B Yang, et al. Clinical therapeutics 2001 23 8 1209 1230 10.1016/S0149-2918(01)80102-8 11558859 (Pubitemid 32804115)
8. Cholesterol lowering and ezetimibe. JM Drazen, JA Jarcho, S Morrissey, GD Curfman, The New England journal of medicine 2008 358 14 1507 1508 10.1056/NEJMe0801842 18376001 (Pubitemid 351482747)
9. Use of ezetimibe in the United States and Canada. CA Jackevicius, JV Tu, JS Ross, DT Ko, HM Krumholz, The New England journal of medicine 2008 358 17 1819 1828 10.1056/NEJMsa0801461 18375999 (Pubitemid 351581194)
10. Simvastatin with or without ezetimibe in familial hypercholesterolemia. JJ Kastelein, F Akdim, ES Stroes, AH Zwinderman, ML Bots, AF Stalenhoef, FL Visseren, EJ Sijbrands, MD Trip, EA Stein, et al. The New England journal of medicine 2008 358 14 1431 1443 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
11. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. VG Athyros, K Tziomalos, AI Kakafika, H Koumaras, A Karagiannis, DP Mikhailidis, The American journal of cardiology 2008 101 4 483 485 10.1016/j.amjcard.2007.09.096 18312762 (Pubitemid 351199439)
12. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? BG Brown, AJ Taylor, The New England journal of medicine 2008 358 14 1504 1507 10.1056/NEJMe0801608 18376002 (Pubitemid 351482746)
13. Role of oxidative stress in atherosclerosis. D Harrison, KK Griendling, U Landmesser, B Hornig, H Drexler, The American journal of cardiology 2003 91 3A 7A 11A 10.1016/S0002-9149(02)03144-2 12645638 (Pubitemid 36351457)
14. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. PO Bonetti, GM Pumper, ST Higano, DR Holmes Jr, JT Kuvin, A Lerman, Journal of the American College of Cardiology 2004 44 11 2137 2141 10.1016/j.jacc.2004.08.062 15582310 (Pubitemid 39576032)
15. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. HR Davis Jr, DS Compton, L Hoos, G Tetzloff, Arteriosclerosis, thrombosis, and vascular biology 2001 21 12 2032 2038 10.1161/hq1201.100260 11742881 (Pubitemid 34219758)
16. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). M Garcia-Calvo, J Lisnock, HG Bull, BE Hawes, DA Burnett, MP Braun, JH Crona, HR Davis Jr, DC Dean, PA Detmers, et al. Proceedings of the National Academy of Sciences of the United States of America 2005 102 23 8132 8137 10.1073/pnas.0500269102 15928087 (Pubitemid 40800055)
17. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. JP Davies, B Levy, YA Ioannou, Genomics 2000 65 2 137 145 10.1006/geno.2000.6151 10783261 (Pubitemid 30314421)
18. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. SW Altmann, HR Davis Jr, LJ Zhu, X Yao, LM Hoos, G Tetzloff, SP Iyer, M Maguire, A Golovko, M Zeng, et al. Science (New York, NY) 2004 303 5661 1201 1204 (Pubitemid 38233587)
19. Lipid Re-screening: What Is the Best Measure and Interval? O Takahashi, PP Glasziou, R Perera, T Shimbo, J Suwa, S Hiramatsu, T Fukui, Heart 2009 19528038
20. Cholesterol and coronary heart disease: predicting risks by levels and ratios. B Kinosian, H Glick, G Garland, Annals of internal medicine 1994 121 9 641 647 7944071
21. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. PM Ridker, N Rifai, NR Cook, G Bradwin, JE Buring, Jama 2005 294 3 326 333 10.1001/jama.294.3.326 16030277 (Pubitemid 41043776)
22. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. E Ingelsson, EJ Schaefer, JH Contois, JR McNamara, L Sullivan, MJ Keyes, MJ Pencina, C Schoonmaker, PW Wilson, RB D'Agostino, et al. Jama 2007 298 7 776 785 10.1001/jama.298.7.776 17699011 (Pubitemid 47263160)
23. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. I Lemieux, B Lamarche, C Couillard, A Pascot, B Cantin, J Bergeron, GR Dagenais, JP Despres, Archives of internal medicine 2001 161 22 2685 2692 10.1001/archinte.161.22.2685 11732933 (Pubitemid 33134844)
24. Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. B Goswami, M Rajappa, V Mallika, S Kumar, DK Shukla, Acta cardiologica 2008 63 6 749 755 10.2143/AC.63.6.2033393 19157171
25. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. JJ Kastelein, WA van der Steeg, I Holme, M Gaffney, NB Cater, P Barter, P Deedwania, AG Olsson, SM Boekholdt, DA Demicco, et al. Circulation 2008 117 23 3002 3009 10.1161/CIRCULATIONAHA.107.713438 18519851
26. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. O Hussein, L Minasian, Y Itzkovich, K Shestatski, L Solomon, J Zidan, British journal of clinical pharmacology 2008 65 5 637 645 10.1111/j.1365-2125.2007.03080.x 18241285 (Pubitemid 351535082)
27. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. T Nakamura, E Sato, N Fujiwara, Y Kawagoe, Y Ueda, T Suzuki, S Ueda, H Adachi, S Okuda, SI Yamagishi, Pharmacol Res 2009
28. Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. R Zhao, X Ma, X Xie, GX Shen, American journal of physiology 2009 297 1 104 111 19401454
29. Vascular protective effects of ezetimibe in ApoE-deficient mice. H Nakagami, MK Osako, Y Takami, R Hanayama, H Koriyama, M Mori, H Hayashi, H Shimizu, R Morishita, Atherosclerosis 2009 203 1 51 58 10.1016/j. atherosclerosis.2008.05.026 18603252
30. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. K Hayashi, S Nakamura, R Morishita, A Moriguchi, M Aoki, K Matsumoto, T Nakamura, Y Kaneda, N Sakai, T Ogihara, Gene therapy 2000 7 19 1664 1671 10.1038/sj.gt.3301284 11083475
31. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. JP Davies, C Scott, K Oishi, A Liapis, YA Ioannou, The Journal of biological chemistry 2005 280 13 12710 12720 10.1074/jbc.M409110200 15671032
32. Localization and role of NPC1L1 in cholesterol absorption in human intestine. AT Sane, D Sinnett, E Delvin, M Bendayan, V Marcil, D Menard, JF Beaulieu, E Levy, Journal of lipid research 2006 47 10 2112 2120 10.1194/jlr.M600174-JLR200 16829661 (Pubitemid 44936122)
33. Inhibition of Hepatic Neiman-Pick C1-Like 1 Improves Hepatic Insulin Resistance. M Nomura, H Ishii, A Kawakami, M Yoshida, American journal of physiology 2009 19654286
34. A central role for JNK in obesity and insulin resistance. J Hirosumi, G Tuncman, L Chang, CZ Gorgun, KT Uysal, K Maeda, M Karin, GS Hotamisligil, Nature 2002 420 6913 333 336 10.1038/nature01137 12447443 (Pubitemid 35398190)
35. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. L Conde de la Rosa, MH Schoemaker, TE Vrenken, M Buist-Homan, R Havinga, PL Jansen, H Moshage, Journal of hepatology 2006 44 5 918 929 10.1016/j.jhep.2005.07.034 16310883
36. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. RF Schwabe, DA Brenner, Am J Physiol Gastrointest Liver Physiol 2006 290 4 583 589 10.1152/ajpgi.00422.2005 16537970
37. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. S Yamagishi, K Nakamura, T Matsui, T Sato, M Takeuchi, Medical hypotheses 2006 66 4 844 846 10.1016/j.mehy.2005.08.022 16188393 (Pubitemid 43181635)
38. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. EA Hughes, I Tracey, S Singhal, J Patel, Medical hypotheses 2006 67 6 1463 1464 10.1016/j.mehy.2006.05.041 16831521 (Pubitemid 44442644)
39. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. S Zheng, L Hoos, J Cook, G Tetzloff, H Davis Jr, M van Heek, JJ Hwa, European journal of pharmacology 2008 584 1 118 124 10.1016/j.ejphar.2008.01.045 18329014
40. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. M Deushi, M Nomura, A Kawakami, M Haraguchi, M Ito, M Okazaki, H Ishii, M Yoshida, FEBS letters 2007 581 29 5664 5670 10.1016/j.febslet.2007.11.023 18022391 (Pubitemid 350179776)
41. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. T Teramoto, J Sasaki, H Ueshima, G Egusa, M Kinoshita, K Shimamoto, H Daida, S Biro, K Hirobe, T Funahashi, et al. Journal of atherosclerosis and thrombosis 2007 14 4 155 158 17827859
42. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. T Teramoto, J Sasaki, H Ueshima, G Egusa, M Kinoshita, K Shimamoto, H Daida, S Biro, K Hirobe, T Funahashi, et al. Journal of atherosclerosis and thrombosis 2007 14 2 45 50 17485887
43. A simple test to monitor oxidative stress. MR Cesarone, G Belcaro, M Carratelli, U Cornelli, MT De Sanctis, L Incandela, A Barsotti, R Terranova, A Nicolaides, Int Angiol 1999 18 2 127 130 10424368 (Pubitemid 29306588)
44. Evaluation of reactive oxygen metabolites with micromethod in neonates: determination of standards of normality in full-term babies. S Parmigiani, L Gambini, A Massari, I Pezzani, C Payer, G Bevilacqua, Acta Biomed Ateneo Parmense 1997 68 Suppl 1 103 106 10021726 (Pubitemid 128516483)
45. Evaluation of endothelial function using finger plethysmography. AK Faizi, DW Kornmo, S Agewall, Clinical physiology and functional imaging 2009 29 5 372 375 10.1111/j.1475-097X.2009.00882.x 19552735